Dexmedetomidine Versus Midazolam Added to Ketamine in Pediatric Patients Undergoing Bone Marrow Aspiration and Biopsy
Status:
Completed
Trial end date:
2019-04-20
Target enrollment:
Participant gender:
Summary
Group I :The patients will receive midazolam intravenously (i.v.) in a dose of 0.05 mg/kg
diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine (iv).
Group II : The patients will receive Dexmedetomidine intravenously (i.v.) in a dose of
2mic/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine (iv).
The objective of this study to evaluate the clinical effects, adverse effects and recovery
time of two different sedative agents (midazolam and Dexmedetomidine) combined with ketamine
during conscious sedation for child patient with haematological cancer undergoing BMA
&biopsy.